Diffuse Large B-Cell Lymphoma Prognosis - R-IPI Score and Risk Band

A DLBCL prognosis calculator is a clinical planning tool that turns five pretreatment findings - age, Ann Arbor stage, ECOG performance status, serum LDH, and the number of extranodal disease sites - into the R-IPI score and the Sehn 2007 risk band, with the published 4-year overall and progression-free survival percentage attached to each band.

Use this DLBCL prognosis calculator when the staging workup is in hand and you want to translate those findings into a Sehn 2007 risk band before the treatment plan is finalized.

• • Pre-treatment risk conversation: Bring a baseline R-IPI band and 4-year survival to a first hematology visit so the treatment plan can be framed around a shared risk picture.
• • Trial enrollment comparison: Compare the patient's R-IPI band to published R-CHOP outcomes so eligibility can be discussed.
• • Age-adjusted IPI for younger patients: Compute the AA-IPI alongside the R-IPI when the patient is 60 or younger to match both the Sehn 2007 and original 1993 scales.
• • Patient and family education: Show the factor breakdown so the family understands what drove the band.

DLBCL is the most common aggressive non-Hodgkin lymphoma in adults, and the R-IPI is the bedside score reported alongside cell-of-origin and double-hit status.

This calculator is for shared decision-making. It does not replace biopsy or staging imaging.

For the related mantle cell lymphoma workup that uses age, ECOG, LDH, and white blood cell count instead of the DLBCL factor list, the MIPI Score calculator returns the matching low, intermediate, or high mantle cell lymphoma band.

The R-IPI score is the sum of five yes/no pretreatment factors first defined in 1993 and regrouped into three risk bands by Sehn and colleagues in 2007.

• Age > 60 years: Counts one factor if older than 60 at diagnosis; dropped from the AA-IPI for patients 60 or younger.
• Stage III or IV: Counts one factor when Ann Arbor stage is III or IV.
• ECOG 2 or higher: Counts one factor when Zubrod performance status is 2, 3, or 4.
• Elevated serum LDH: Counts one factor when LDH is above the local upper normal limit.
• More than 1 extranodal site: Counts one R-IPI factor; not used in the AA-IPI.

The score runs as a 0 to 5 integer. The band is read off the published table: 0 = Very good (94 percent 4-year overall survival, 94 percent progression-free); 1 to 2 = Good (79 percent overall, 80 percent progression-free); 3 to 5 = Poor (55 percent overall, 53 percent progression-free).

For patients 60 or younger, the calculator runs the original age-adjusted IPI on stage, ECOG, and LDH and assigns Low, Low-intermediate, High-intermediate, or High risk.

According to Sehn et al. - Revised International Prognostic Index (Blood 2007), the Revised International Prognostic Index for diffuse large B-cell lymphoma uses the same five pretreatment factors as the 1993 IPI and assigns patients to one of three risk bands, with a 94 percent 4-year overall survival in the Very good band, 79 percent in the Good band, and 55 percent in the Poor band.

For another published cancer prognostic tool that sums clinical factors into a probability band, the Breast Cancer Risk Calculator applies the Gail 1989 relative risks to SEER baseline rates for 5-year and lifetime invasive breast cancer risk.

Four clinical concepts drive every number this DLBCL prognosis calculator returns.

When the calculator and the staging letter disagree, the discrepancy usually comes from a different LDH reference range, an updated ECOG, or a pathology addendum.

The same five-factor yes/no logic appears in pulmonary embolism workups, where the Revised Geneva Score calculator combines age, surgery, heart rate, and other binary findings into a low, intermediate, or high pre-test probability band.

Walk through the inputs in order and read the band off the result panel. Each step is one piece of information already in the staging letter.

1. 1 Enter the patient's age at diagnosis: Use whole years of age at the time of the DLBCL workup, not the current age. The calculator clamps to the 18 to 100 range used in the Sehn 2007 cohort.
2. 2 Select the Ann Arbor stage: Pick the stage from the staging letter (I, II, III, or IV). Stage III or IV contributes one factor.
3. 3 Select the ECOG performance status: Use the Zubrod score from the consult note (0 to 4). Status of 2 or higher contributes one factor.
4. 4 Pick the serum LDH result: Choose Normal or Elevated based on whether LDH was above the local upper normal limit at diagnosis.
5. 5 Enter the number of extranodal sites: Count distinct extranodal disease sites on the staging workup. More than 1 contributes one R-IPI factor.
6. 6 Read the band and survival: Read the R-IPI band, the 4-year overall survival, and the 4-year progression-free survival. If the patient is 60 or younger, also read the age-adjusted IPI band.

For a 65-year-old with stage IV DLBCL, ECOG 1, elevated LDH, and two extranodal sites, the calculator returns R-IPI 4 (Poor band, 55 percent 4-year overall, 53 percent progression-free). The AA-IPI row is hidden.

For a similar bedside tally that sums yes/no clinical findings into a low, intermediate, or high probability band, the 4Ts Score calculator returns the heparin-induced thrombocytopenia pretest probability from the same kind of structured factor checklist.

A bedside score is useful only when it lines up with how the oncology team uses a DLBCL prognosis calculator in routine practice.

• • Frame the first hematology visit: Arrive with the R-IPI band and 4-year survival calculated so the visit moves from explaining the score to treatment choices.
• • Compare cohort outcomes: Read the patient's band against the Sehn 2007 cohort curve so trial enrollment can be discussed in numbers.
• • Keep the AA-IPI visible for younger patients: Show the AA-IPI band alongside the R-IPI when the patient is 60 or younger for crosswalks.
• • Make the factor mix transparent: List the factor totals so the family can see which item pushed the score up rather than reading a black-box band.
• • Plan PET-based response assessment: Use the band to anchor the conversation about interim PET after R-CHOP.

These benefits assume the staging workup is complete. When the LDH reference range is unclear, the staging letter wins.

For another bedside prognostic index that pairs a clinical checklist with a 4-year survival curve, the BODE Index calculator walks through the COPD mortality score using BMI, airflow obstruction, dyspnea, and exercise capacity.

Five pretreatment findings drive the R-IPI band.

• • The R-IPI was derived from an early rituximab-era R-CHOP cohort. Modern regimens, intensified front-line therapy, and CAR-T referral can shift individual outcomes beyond the published 4-year survival percentages.
• • Cell-of-origin, double-hit, and double-expressor status refine prognosis within each R-IPI band and are reported alongside the score.
• • The calculator does not include primary mediastinal large B-cell lymphoma, primary CNS lymphoma, or transformed DLBCL.

Read the band as a starting point, not a fixed forecast. The 4-year overall survival is a population average; individual outcomes vary with induction response and interim PET findings.

According to Zhou et al. - An enhanced International Prognostic Index (NCCN-IPI) for diffuse large B-cell lymphoma (Blood 2014), the R-IPI and the enhanced NCCN-IPI remain the standard clinical risk stratification tools for DLBCL in the rituximab era, with molecular classifiers reported alongside the IPI family.

When a urology colleague wants a comparable risk score for non-muscle-invasive bladder cancer, the EORTC Bladder Cancer Calculator returns the EORTC point total in the same yes/no factor style.